ABTB2: A Protein Implicated in Neurological Disorders and Potential Therapeutic Target

Target Name: ABTB2

NCBI ID: G25841

ABTB2

ABTB2: A Protein Implicated in Neurological Disorders and Potential Therapeutic Target

ABTB2 (BTBD22) is a protein that is expressed in the brain and is known for its role in the development and progression of various neurological disorders, including Alzheimer's disease. The protein is a key component of the huntingtin protein family, which is a family of transmembrane proteins that are involved in a variety of cellular processes, including stress response, neurotransmitter signaling, and cell survival.

ABTB2 is a 21-kDa protein that is expressed in the brain and is highly conserved across different species, including humans. It is localized to the endoplasmic reticulum and is predominantly expressed in the prefrontal cortical cortical region of the brain. The protein is involved in the formation of huntingtin protein Complex (HCP), which is a key regulator of neuronal excitability and is implicated in the development of various neurological disorders.

In addition to its role in HCP formation, ABTB2 is also involved in the regulation of neuronal excitability and in the modulation of synaptic plasticity. It has been shown to play a role in the regulation of neurotransmitter release and in the modulation of action potential (AP ) dynamics in neurons.

The search for potential drug targets and biomarkers for ABTB2 has led to the identification of several potential targets. One of the most promising targets is the protein kinase B3 (PKB/AKT), which is a known regulator of ABTB2 activity. The addition of a Pharmacological agents that can inhibit PKB/AKT signaling have been shown to reduce the expression of ABTB2 and to protect against the neurotoxicity associated with ABTB2-mediated signaling.

Another potential target for ABTB2 is the protein tyrosine phosphatase (PTP), which is known to regulate the activity of ABTB2. The addition of a pharmacological agent that can inhibit PTP activity has been shown to reduce the expression of ABTB2 and to protect against the neurotoxicity associated with ABTB2-mediated signaling.

In addition to these targets, there is also interest in the use of ABTB2 as a biomarker for the diagnosis and progression of neurological disorders. The expression of ABTB2 has been shown to be decreased in the brains of individuals with Alzheimer's disease, and it is possible that ABTB2 may serve as a diagnostic or predictive biomarker for the disease.

ABTB2 is also of interest as a potential therapeutic target for the treatment of neurological disorders. The neurotoxicity associated with ABTB2-mediated signaling makes it a potential candidate for small molecule inhibitors. For example, inhibitors of ABTB2 have been shown to be effective in protecting against neurotoxicity in rat models of neurotoxicity, including the neurotoxicity associated with ABTB2-mediated signaling.

In conclusion, ABTB2 is a protein that is of interest as a drug target or biomarker for the development and progression of various neurological disorders. The expression of ABTB2 is decreased in the brains of individuals with Alzheimer's disease and its neurotoxicity has been implicated in the development of the disease. The addition of pharmacological agents that can inhibit ABTB2-mediated signaling has been shown to be effective in protecting against neurotoxicity and in reducing the expression of ABTB2. Further research is needed to fully understand the role of ABTB2 in the development and progression of neurological disorders and to develop effective treatments.

Protein Name: Ankyrin Repeat And BTB Domain Containing 2

Functions: May be involved in the initiation of hepatocyte growth

The "ABTB2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ABTB2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets